HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy.

Abstract
We report a 76-year-old woman with extra nodal NK/T-cell lymphoma nasal type (ENKL). She had large tumors on her left leg with inguinal lymphadenopathy and gastric tumors. The tumor cells showed angiocentric growth with necrosis. Immunohistologically, the tumor cells from the skin lesion expressed CD2, cytoplasmic CD3, CD56, and T-cell intracellular antigen-1 (TIA-1), but not surface CD3, CD19, and TdT. The gastric tumor cell, also expressed cytoplasmic CD3, CD45RO and CD56. She was diagnosed as having ENKL (stage IV of Ann Arbor). The tumors responded remarkably well to radiation therapy followed by multi-drug resistance independent DeVIC (carboplatin, etoposide, ifosfamide, and dexamethasone) combination therapy. After two series of this therapy, no tumors were detected in clinical, histopathological, endoscope and computerized tomogram (CT) examinations. However, she suddenly died of brain stem metastasis three months later. Although there may be a limitation of effects on metastasis of tumors in the central nervous system, radiation and DeVIC combination therapy is a potent therapeutic method for ENKL.
AuthorsEriko Nomura, Ken-ichi Isoda, Keiichi Yamanaka, Motoko Yamaguchi, Arata Hakamada, Hitoshi Mizutani
JournalThe Journal of dermatology (J Dermatol) Vol. 32 Issue 3 Pg. 204-9 (Mar 2005) ISSN: 0385-2407 [Print] England
PMID15863868 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Etoposide
  • Dexamethasone
  • Carboplatin
  • Ifosfamide
Topics
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biopsy, Needle
  • Carboplatin (therapeutic use)
  • Combined Modality Therapy
  • Dexamethasone (therapeutic use)
  • Disease Progression
  • Etoposide (therapeutic use)
  • Fatal Outcome
  • Female
  • Humans
  • Ifosfamide (therapeutic use)
  • Immunohistochemistry
  • Killer Cells, Natural (pathology)
  • Lymphoma, T-Cell, Peripheral (pathology, therapy)
  • Neoplasm Invasiveness (pathology)
  • Neoplasm Staging
  • Radiotherapy, Adjuvant
  • Skin Neoplasms (pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: